Department of Medical and Surgical Sciences for Mother, Child and Adult, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy.
Ann Med. 2021 Dec;53(1):908-915. doi: 10.1080/07853890.2021.1938662.
To evaluate the actual perceptions of hormonal contraceptives (HC) in women of reproductive age in comparison with similar concerns of postmenopausal women in relation to hormone therapy (HT).
A questionnaire-based study was conducted in a population of 370 women, 198 (53.5%) premenopausal and 172 (46.5%) postmenopausal. Perceptions were evaluated using specific questions and Likert scales (-5 to +5).Multivariate regression analyses were adjusted for categories of HC/HT use (never, past and current).
The most reported adverse effect associated with hormonal treatments was venous thrombosis (1.4 ± 0.1), especially for HC use in premenopausal women ( < .0001). According to responses, hormonal treatments can increase the risk of developing venous thrombosis (OR 0.79; 95% CI 0.67-0.96, = .004) and depression (OR 0.80; 95% CI 0.69-0.92, = .002) more in pre-menopause, while they can increase the risk of weight gain more in post-menopause (OR 1.24: 95% CI 1.07-1.42, = .003).The greatest oncological concern throughout life was about breast cancer (0.9 ± 0.1). There was the perception that hormonal treatments can increase the risk of developing ovarian cancer more in post-menopause (OR 1.44; 95% CI 1.19-1.75, = .0002), while they can increase the risk of uterine cervix cancer more in pre-menopause (OR 0.74; 95% CI 0.52-0.97, = .03).
Our data suggest that our patients are primarily concerned about the effects of hormonal treatments on venous thrombosis, mood, breast cancer and cervical cancer risk, and, later in life, about their impact on weight gain, breast and ovarian cancer risk.KEY MESSAGESYoung patients are primarily concerned about the effects of hormonal treatments on venous thrombosis, mood, breast cancer and cervical cancer risk.Older patients are primarily concerned about the effects of hormonal treatments on weight gain, breast and ovarian cancer risk.The greatest oncological concern throughout life was about breast cancer.
本研究旨在评估生育年龄女性对激素避孕(HC)的实际认知,并与接受激素治疗(HT)的绝经后女性进行对比。
本研究采用问卷调查的方式,共纳入 370 名女性,其中 198 名为绝经前女性(53.5%),172 名为绝经后女性(46.5%)。通过特定问题和李克特量表(-5 至+5)评估认知。多变量回归分析针对 HC/HT 的使用类别(从未、过去和现在)进行了调整。
与激素治疗相关的最常见不良反应是静脉血栓栓塞(1.4±0.1),尤其是在绝经前女性中( < .0001)。根据应答结果,激素治疗会增加静脉血栓栓塞(OR 0.79;95% CI 0.67-0.96, = .004)和抑郁(OR 0.80;95% CI 0.69-0.92, = .002)的发生风险,且在绝经前女性中更为显著,而在绝经后女性中会增加体重增加的风险(OR 1.24:95% CI 1.07-1.42, = .003)。一生中最大的癌症顾虑是乳腺癌(0.9±0.1)。有观点认为,激素治疗会增加绝经后女性发生卵巢癌(OR 1.44;95% CI 1.19-1.75, = .0002)的风险,而会增加绝经前女性宫颈癌(OR 0.74;95% CI 0.52-0.97, = .03)的风险。
我们的数据表明,患者主要关注激素治疗对静脉血栓栓塞、情绪、乳腺癌和宫颈癌风险的影响,而在后期生活中则主要关注激素治疗对体重增加、乳腺癌和卵巢癌风险的影响。
年轻患者主要关注激素治疗对静脉血栓栓塞、情绪、乳腺癌和宫颈癌风险的影响。老年患者主要关注激素治疗对体重增加、乳腺癌和卵巢癌风险的影响。一生中最大的癌症顾虑是乳腺癌。